Role of anoikis-related gene PLK1 in kidney renal papillary cell carcinoma: a bioinformatics analysis and preliminary verification on promoting proliferation and migration

Gan, Li; Xiao, Qiyu; Zhou, Yusong; Fu, Ying; Tang, Mengjie

doi:10.3389/fphar.2023.1211675

Cited by 3 publications

(2 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, they delved deeper into the functional significance of Plk1 in KIRP and uncovered that silencing Plk1 in KIRP significantly curtailed cell proliferation, clonogenicity, and migratory capacity. 55 Thus, this creates newer avenues for research in generating potential drugs for RCC along with other grave tumor-related kidney disorders in the near future.…”

Section: Plk1 In Ktsmentioning

confidence: 99%

Targeting polo‐like kinase 1 to treat kidney diseases

Kulkarni,

Dagar,

Gaikwad

2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

Globally, ∼850 million individuals suffer from some form of kidney disease. This staggering figure underscores the importance of continued research and innovation in the field of nephrology to develop effective treatments and improve overall global kidney health. In current research, the polo‐like kinase (Plk) family has emerged as a group of highly conserved enzyme kinases vital for proper cell cycle regulation. Plks are defined by their N‐terminal kinase domain and C‐terminal polo‐box domain, which regulate their catalytic activity, subcellular localization, and substrate recognition. Among the Plk family members, Plk1 has garnered significant attention due to its pivotal role in regulating multiple mitotic processes, particularly in the kidneys. It is a crucial serine–threonine (Ser‐Thr) kinase involved in cell division and genomic stability. In this review, we delve into the types and functions of Plks, focusing on Plk1's significance in processes such as cell proliferation, spindle assembly, and DNA damage repair. The review also underscores Plk1's vital contributions to maintaining kidney homeostasis, elucidating its involvement in nuclear envelope breakdown, anaphase‐promoting complex/cyclosome activation, and the regulation of mRNA translation machinery. Furthermore, the review discusses how Plk1 contributes to the development and progression of kidney diseases, emphasizing its overexpression in conditions such as acute kidney injury, chronic kidney disease, and so forth. It also highlights the importance of exploring Plk1 modulators as targeted therapies for kidney diseases in future. This review will help in understanding the role of Plk1 in kidney disease development, paving the way for the discovery and development of novel therapeutic approaches to manage kidney diseases effectively.

show abstract

Section: Plk1 In Ktsmentioning

confidence: 99%

Targeting polo‐like kinase 1 to treat kidney diseases

Kulkarni,

Dagar,

Gaikwad

2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…Recent studies have shown that anoikis has potential therapeutic value in RCC. Some anoikis key genes was reported to promote proliferation and migration in RCC [ 6 ]. In addition, progression of RCC can be inhibited by reversing anoikis resistance [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Validation and identification of anoikis-related lncRNA signatures for improving prognosis in clear cell renal cell carcinoma

Zhu,

Wang,

Zeng

et al. 2024

Aging

View full text Add to dashboard Cite

Background: Clear cell carcinoma (ccRCC) usually has a high metastasis rate and high mortality rate. To enable precise risk stratification, there is a need for novel biomarkers. As one form of apoptosis, anoikis results from the disruption of cell-cell connection or cell-ECM attachment. However, the impact of anoikis-related lncRNAs on ccRCC has not yet received adequate attention. Methods: The study utilized univariate Cox regression analysis in order to identify the overall survival (OS) associated anoikis-related lncRNAs (ARLs), followed by the LASSO algorithm for selection. On this basis, a risk model was subsequently established using five anoikis-related lncRNAs. To dig the inner molecular mechanism, KEGG, GO, and GSVA analyses were conducted. Additionally, the immune infiltration landscape was estimated using the ESTIMATE, CIBERSORT, and ssGSEA algorithms. Results: The study constructed a novel risk model based on five ARLs (AC092611.2, AC027601.2, AC103809.1, AL133215.2, and AL162586.1). Patients categorized as low-risk exhibited significantly better OS. Notably, the study observed marked different immune infiltration landscapes and drug sensitivity by risk stratification. Additionally, the study preliminarily explored potential signal pathways associated with risk stratification. Conclusion: The study exhibited the crucial role of ARLs in the carcinogenesis of ccRCC, potentially through differential immune infiltration. Furthermore, the established risk model could serve as a valuable stratification factor for predicting OS prognosis.

show abstract

Pan-Cancer Genetic Profiles of Mitotic DNA Integrity Checkpoint Protein Kinases

Rasteh,

Liu,

Wang

2024

Preprint

View full text Add to dashboard Cite

BACKGROUND: The mitotic DNA integrity checkpoint signaling pathway is potentially involved in cancers that regulate genomic stability where protein kinases play a pivotal role. 16 total protein kinase genes are involved in this pathway: ATM, BRSK1, CDK1, CDK2, CHEK1, CHEK2, MAP3K20, NEK11, PLK1, PLK2, PLK3, PRKDC, STK33, TAOK1, TAOK2, and TAOK3. This study aims to provide pan-cancer profiles of the protein kinases in mitotic DNA integrity checkpoint signaling gene set for potential prognostic and diagnostic purposes, as well as future potential therapeutic targets for cancer in a clinical setting. METHODS: Multi-omic data was acquired for the 16 genes; over 9000 samples of 33 types of cancer were analyzed to create pan-cancer profiles of SNV, CNV, methylation, mRNA expression, pathway crosstalk, and microRNA regulation networks. RESULTS: The SNV profile showed that most of these genes have a high SNV mutation frequency across some cancer types, such as UCEC and SKCM. The CNVs of some of these genes are associated with the survival of UCEC, KIRP, and LGG. BRCA, KIRC, LUAD, and STAD might be affected by the mRNA expression of these genes which might involve regulation of copy number, methylation, and miRNA. In addition, these genes also cross-talk with some known cancer pathways. CONCLUSION: The protein kinases in mitotic DNA integrity checkpoint signaling may play a role in cancer development and, with adequate research, could potentially be developed as biomarkers for cancer diagnosis and prognosis. However, further efforts are necessary to validate their clinical value for diagnosis and prognosis and to develop practical applications in clinical settings. Nevertheless, these pan-cancer profiles offer a better overall understanding as well as useful information for future reference regarding mitotic DNA integrity checkpoint signaling in cancer.

show abstract

Role of anoikis-related gene PLK1 in kidney renal papillary cell carcinoma: a bioinformatics analysis and preliminary verification on promoting proliferation and migration

Cited by 3 publications

References 51 publications

Targeting polo‐like kinase 1 to treat kidney diseases

Targeting polo‐like kinase 1 to treat kidney diseases

Validation and identification of anoikis-related lncRNA signatures for improving prognosis in clear cell renal cell carcinoma

Pan-Cancer Genetic Profiles of Mitotic DNA Integrity Checkpoint Protein Kinases

Contact Info

Product

Resources

About